Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7416452 | 1.00 | USP2 (0.69) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7797653 | 1.00 | USP2 (0.69) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9494373 | 0.90 | USP2 (0.72) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5172119 | 0.90 | USP2 (0.72) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL346937 | 0.90 | USP2 (0.72) | USP2PSEN1PSEN2APH1BNCSTN | |
| Hydrochloric Acid SCHEMBL5171901 | 0.89 | USP2 (0.71) | USP2PSEN1PSEN2APH1BNCSTN | |
| Hydrochloric Acid SCHEMBL5171904 | 0.89 | USP2 (0.71) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5711260 | 0.88 | USP2 (0.61) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7628748 | 0.88 | USP2 (0.61) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5711389 | 0.88 | USP2 (0.61) | USP2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| US-8039480-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2011-10-18 | — | — | US | disclosed |
| EP-1781602-A1 | 4-SULFONYL-SUBSTITUTED BENZOYLALANINE DERIVATIVES USEFUL AS KYNURENINE-AMINOTRANSFERASE INHIBITORS | PELLICCIARI, Roberto (IT) | 2007-05-09 | — | — | EP | disclosed |
| EP-1103560-B1 | NOVEL THIAZOLIDINE DERIVATIVES | SANTEN PHARMACEUTICAL CO LTD (JP) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006013085-A1 | 4-SULFONYL-SUBSTITUTED BENZOYLALANINE DERIVATES USEFUL AS KYNURENINE-AMINOTRANSFERASE INHIBITORS | PELLICCIARI ROBERTO (IT) | 2006-02-09 | — | — | WO | disclosed |
| US-6410576-B1 | ANTIINFLAMMATORY AGENTS; CARDIOVASCULAR DISORDERS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-25 | — | — | US | disclosed |
| US-20010008947-A1 | 2-AMINO-4-PHENYL-4-OXO-BUTYRIC ACID DERIVATIVES | VARASI MARIO (IT) | 2001-07-19 | — | — | US | disclosed |
| EP-1103560-A1 | NOVEL THIAZOLIDINE DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
| EP-0663899-B1 | SUBSTITUTED KYNURENINES, A PROCESS FOR THEIR PREPARATION, AND USE AS MEDICAMENTS | UNIV MARYLAND (US) | 1999-06-30 | — | — | EP | disclosed |
| EP-0919538-A1 | Substituted kynurenines, a process for their preparation, and use as medicaments | THE UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0663899-A4 | SUBSTITUTED KYNURENINES, A PROCESS FOR THEIR PREPARATION, AND USE AS MEDICAMENTS. | UNIV MARYLAND (US) | 1996-01-17 | — | — | EP | disclosed |
| US-5484814-A | NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1996-01-16 | — | — | US | disclosed |
| US-5470870-A | New class of excitatory amino acid antagonist for epilepsy, anxiety or stroke | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0663899-A1 | SUBSTITUTED KYNURENINES, A PROCESS FOR THEIR PREPARATION, AND USE AS MEDICAMENTS | THE UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1995-07-26 | — | — | EP | disclosed |
| WO-1995004714-A1 | SUBSTITUTED KYNURENINES, A PROCESS FOR THEIR PREPARATION, AND USE AS MEDICAMENTS | UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1995-02-16 | — | — | WO | disclosed |
| EP-0501378-B1 | NMDA Antagonists | MERRELL DOW PHARMA (US) | 1995-01-11 | — | — | EP | disclosed |
| US-5360814-A | NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-11-01 | — | — | US | disclosed |
| EP-0532545-A1 | NICOTINYLALANINE AS A THERAPEUTIC AGENT ACTING ON THE CENTRAL NERVOUS SYSTEM | FIDIA S.p.A. (IT) | 1993-03-24 | — | — | EP | disclosed |
| EP-0501378-A1 | NMDA Antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-09-02 | — | — | EP | disclosed |
| WO-1991017750-A1 | NICOTINYLALANINE AS A THERAPEUTIC AGENT ACTING ON THE CENTRAL NERVOUS SYSTEM | FIDIA S.P.A. (IT) | 1991-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | USP2 763/4885PSEN1 699/4885PSEN2 1379/4885 |
| US-20010008947-A1 | 2-AMINO-4-PHENYL-4-OXO-BUTYRIC ACID DERIVATIVES | KYNU, KMO, ABAT | USP2 861/4885PSEN1 70/4885PSEN2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.